What is Medeloop?
Medeloop operates at the intersection of artificial intelligence and life sciences, providing an end-to-end platform designed to modernize the clinical research landscape. By automating complex workflows and enhancing data integrity, the company enables researchers to conduct trials with greater speed and precision. Its market position is defined by its ability to bridge the gap between raw clinical data and actionable insights, a critical requirement for modern pharmaceutical and biotech development. As the industry faces increasing pressure to reduce time-to-market for new therapies, Medeloop's technology serves as a vital infrastructure layer for the next generation of medical innovation.
How much funding has Medeloop raised?
Medeloop has raised a total of $23.5M across 2 funding rounds:
Angel/Seed
$8M
Series A
$15.5M
Angel/Seed (2023): $8M with participation from Maven Ventures and General Catalyst
Series A (2024): $15.5M led by Icon Ventures, General Catalyst, Inovia, and Maven Ventures
Key Investors in Medeloop
Icon Ventures
Icon Ventures is an early-stage venture capital fund based in Palo Alto, CA, specializing in investing in AI-native and AI-powered companies.
General Catalyst
General Catalyst operates as a venture capital firm focused on identifying and supporting transformational business opportunities across multiple sectors and stages.
Inovia
iNovia Capital is a full-stack venture firm that partners with founders to build enduring global technology companies by prioritizing human-centric investment strategies.
What's next for Medeloop?
With this latest infusion of capital, Medeloop is expected to prioritize the expansion of its technical infrastructure and the scaling of its operational capabilities to support larger, multi-site clinical trials. The strategic focus will likely shift toward deepening its AI capabilities to handle more complex datasets and expanding its footprint within the global research ecosystem. By maintaining its focus on high-impact, AI-native solutions, the company is poised to become a standard-bearer for digital transformation in clinical research, potentially setting the stage for future partnerships with major pharmaceutical entities and research institutions.
See full Medeloop company page
